You need to enable JavaScript to run this app.
Recon: US signs $1.5B deal for Moderna coronavirus vaccine; Mesoblast GVHD therapy faces clinical, manufacturing questions ahead of adcomm
Recon
Michael Mezher
ReconMichael Mezher
ReconMichael Mezher